First COVID-19 vaccine tested on humans raises hopes for cure through its early trial results
New Delhi | Jagran Lifestyle Desk: The first-ever COVID vaccine to be tested in the humans,l has given promising results in the United States of America, by stimulating a strong immune response in the first eight individuals who volunteered for the testing.
The experimental vaccine has been held 'safe', and the maker of the Vaccine, Moderna, announced on Monday that it is functioning on an an accelerated timetable to begin larger human trials soon, New York Times reported.
The initial findings suggest that the first eight volunteers received two doses of experimental vaccine, and each time the vaccine provoked strong immune responses detrimental to COVID-19's growth in the body.
Moderna’s technology, which involves the destruction of the genetic material from the virus called mRNA, is relatively new and exceptional in conception and its positive response in finding cure against COVID-19 has been touted to be 'promising' by the experts.
The New York Times report says that as soon as the news of COVID vaccine's promising pathway came, Moderna’s stock shot up by more than 25 percent on Monday afternoon and helped drive Wall Street to its best day in six weeks.
The development of vaccines are being seen as the only way ahead en route to the cure of the contagion viral infection which has infected over 4.8 million people and left over 318,000 people dead worldwide, according to the latest data available on Johns Hopkins University's COVID-tracker.
Numerous medical and serological research firms across the world are working tirelessly for a clinically relevant COVID vaccine. The trial in humans for COVID vaccine have already started by several manufacturers, including Pfizer and its German partner BioNTech and the University of Oxford's Jenner Institure, which is working with AstraZeneca and has tied up with Pune-based Serological Institute of India for the vaccine production.
Also, the Hyderabad-based Bharat Biotech has partnered with the US-based FluGen and University of Wisconsin Madison, for producing 300 million doses of CoroFlu, a COVID-19 vaccine which could be in human clinical trials by the fall of 2020.
Posted By: Abhinav Gupta